Browsing by Author "Martínez Bosch, Neus"

Sort by: Order: Results:

  • A novel translational control mechanism involving RNA structures within coding sequences
    Jungfleisch, Jennifer, 1986-; Nedialkova, Danny D.; Dotu, Ivan; Sloan, Katherine E.; Martínez Bosch, Neus; Brüning, Lukas; Raineri, Emanuele; Navarro Medrano, Pilar; Bohnsack, Markus T.; Leidel, Sebastian; Díez Antón, Juana, 1962- (Cold Spring Harbor Laboratory Press (CSHL Press), 2017)
    The impact of RNA structures in coding sequences (CDS) within mRNAs is poorly understood. Here, we identify a novel and highly conserved mechanism of translational control involving RNA structures within coding sequences ...
  • Characterization of Galectin-1 in Pancreatic Cancer: A sweet target for a bitter disease
    Martínez Bosch, Neus (Universitat Pompeu Fabra, 2012-05-04)
    Pancreatic cancer is nowadays one of the neoplasms with worst prognosis, so research towards the discovery of new molecular targets for therapy and diagnosis is more than urgent. In this direction, we have deeply evaluated ...
  • Electrochemical immunosensing of ST2: A checkpoint target in cancer diseases
    Torrente-Rodríguez, Rebeca M.; Muñoz-San Martín, Cristina; Gamella, Maria; Pedrero, María; Martínez Bosch, Neus; Navarro Medrano, Pilar; García de Frutos, Pablo; Pingarrón, José M.; Campuzano, Susana (MDPI, 2021)
    A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed ...
  • Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker
    Martínez Bosch, Neus; Alameda Quitllet, Francisco; Arumí Uría, Montserrat; Bellosillo Paricio, Beatriz; Menéndez, Silvia; Esteve-Codina, Anna; Martínez-García, Maria; Navarro Medrano, Pilar (MDPI, 2023)
    Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a ...
  • Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
    Martínez Bosch, Neus; Vinaixa Forner, Judith, 1991-; Navarro Medrano, Pilar (MDPI, 2018)
    Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer, remains one of the most challenging problems for the biomedical and clinical fields, with abysmal survival rates and poor therapy efficiency. ...
  • Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker
    Martínez Bosch, Neus; Barranco Priego, Luis Eugenio; Orozco, Carlos Alberto; Moreno, Mireia; Visa Turmo, Laura; Iglesias Coma, Mar; Oldfield, Lucy; Neoptolemos, John; Greenhalf, William; Earl, Julie; Carrato, Alfredo; Costello, Eithne; Navarro Medrano, Pilar (Impact Journal, 2018)
    Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that ...
  • Peptides against low density lipoprotein (LDL) aggregation inhibit intracellular cholesteryl ester loading and proliferation of pancreatic tumor cells
    Benitez-Amaro, Aleyda; Martínez Bosch, Neus; Manero Rupérez, Noemí; Claudi, Lene; La Chica Lhoëst, Maria Teresa; Soler, Marta; Ros Blanco, Lia; Navarro Medrano, Pilar; Llorente-Cortés, Vicenta (MDPI, 2022)
    Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) ...
  • Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.
    Martínez Bosch, Neus; Fernández-Zapico, Martin E.; Navarro Medrano, Pilar; Yélamos López, José (Elsevier, 2016)
    The poly(ADP-ribose) polymerase (PARP) enzymes were initially characterized as sensors of DNA breaks but are now known to play key roles not only in the DNA damage response but also in regulating numerous molecular processes, ...
  • Sialyltransferase inhibitor Ac53FaxNeu5Ac reverts the malignant phenotype of pancreatic cancer cells, and reduces tumor volume and favors T-cell infiltrates in mice
    Miró, Laura; López, Júlia; Guerrero, Pedro E.; Martínez Bosch, Neus; Manero Rupérez, Noemí; Moreno, Mireia; Ortiz, María Rosa; Llop Escorihuela, Esther; Navarro Medrano, Pilar; Peracaula, Rosa (MDPI, 2022)
    Hypersialylation is a feature of pancreatic ductal adenocarcinoma (PDA) and it has been related to tumor malignancy and immune suppression. In this work, we have evaluated the potential of the sialyltransferase inhibitor, ...
  • Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
    Martínez Bosch, Neus; Cristóbal, Helena; Iglesias Coma, Mar; Gironella, Meritxell; Barranco Priego, Luis Eugenio; Visa Turmo, Laura; Calafato, Domenico; Jiménez-Parrado, Silvia; Earl, Julie; Carrato, Alfredo; Manero Rupérez, Noemí; Moreno, Mireia; Morales, Albert; Guerra, Carmen; Navarro Medrano, Pilar; García de Frutos, Pablo (Elsevier, 2022)
    Background: Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here ...
  • Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk
    Orozco, Carlos Alberto; Martínez Bosch, Neus; Enrique Guerrero, Pedro; Vinaixa Forner, Judith, 1991-; Dalotto-Moreno, Tomás; Iglesias García, Mar; Moreno, Mireia; Djurec, Magdolna; Poirier, Françoise; Gabius, Hans J.; Fernández-Zapico, Martin E.; Hwang, Rosa F.; Guerra, Carmen; Rabinovich, Gabriel A.; Navarro Medrano, Pilar (National Academy of Sciences, 2018)
    Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard therapies. A more comprehensive understanding of the ...
  • The Galectin family as molecular targets: hopes for defeating pancreatic cancer
    Manero Rupérez, Noemí; Martínez Bosch, Neus; Barranco Priego, Luis Eugenio; Visa Turmo, Laura; Navarro Medrano, Pilar (MDPI, 2020)
    Galectins are a family of proteins that bind β-galactose residues through a highly conserved carbohydrate recognition domain. They regulate several important biological functions, including cell proliferation, adhesion, ...
  • The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
    Martínez Bosch, Neus; Enrique Guerrero, Pedro; Moreno, Mireia; José Segarra-Martínez, Anabel; Iglesias García, Mar; Munné-Collado, Jessica; Anta Rodríguez, Héctor, 1988-; Gibert, Joan; Orozco, Carlos Alberto; Vinaixa Forner, Judith, 1991-; Fillat i Fonts, Cristina; Viñals, Francesc; Navarro Medrano, Pilar (Impact Journals, 2016)
    Current treatments for pancreatic ductal adenocarcinoma (PDA) are ineffective, making this the 4th leading cause of cancer deaths. Sunitinib is a broad-spectrum inhibitor of tyrosine kinase receptors mostly known for its ...
  • Validation of ZIP4 as a tumour-associated antigen for nanotargeting
    Xu, Ruixue; Martínez Bosch, Neus; Rivera Hueto, Francisco; Mulens-Arias, Vladimir; Rubio Moscardó, Fanny; Conesa, José Javier; Navarro, Pilar; Vicente García, Rubén, 1978-; Rivera Gil, Pilar, 1976- (Taylor & Francis, 2024)
    Pancreatic ductal adenocarcinoma remains a highly aggressive and untreatable cancer. There is a need to develop a new PDAC-associated antigen-targeting drug delivery system to tackle this disease. We validated choosing ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking